645 related articles for article (PubMed ID: 29502162)
21. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
Bambauer R; Olbricht CJ; Schoeppe E
Ther Apher; 1997 Aug; 1(3):242-8. PubMed ID: 10225746
[TBL] [Abstract][Full Text] [Related]
22. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
23. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
[TBL] [Abstract][Full Text] [Related]
24. Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
Sanna C; Stéphenne X; Revencu N; Smets F; Sassolas A; Di Filippo M; Descamps OS; Sokal EM
Atherosclerosis; 2016 Apr; 247():97-104. PubMed ID: 26894473
[TBL] [Abstract][Full Text] [Related]
25. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
Luirink IK; Hutten BA; Greber-Platzer S; Kolovou GD; Dann EJ; de Ferranti SD; Taylan C; Bruckert E; Saheb S; Oh J; Driemeyer J; Farnier M; Pape L; Schmitt CP; Novoa FJ; Maeser M; Masana L; Shahrani A; Wiegman A; Groothoff JW
Atherosclerosis; 2020 Apr; 299():24-31. PubMed ID: 32199148
[TBL] [Abstract][Full Text] [Related]
26. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
27. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Robinson JG
J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
[TBL] [Abstract][Full Text] [Related]
28. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M
J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
[TBL] [Abstract][Full Text] [Related]
30. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L
J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070
[TBL] [Abstract][Full Text] [Related]
31. Familial hypercholesterolemia treatments: Guidelines and new therapies.
Raal FJ; Hovingh GK; Catapano AL
Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
[TBL] [Abstract][Full Text] [Related]
32. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.
Raal FJ; Santos RD
Atherosclerosis; 2012 Aug; 223(2):262-8. PubMed ID: 22398274
[TBL] [Abstract][Full Text] [Related]
33. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
Lappegård KT; Enebakk T; Thunhaug H; Hovland A
Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
[TBL] [Abstract][Full Text] [Related]
34. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
[TBL] [Abstract][Full Text] [Related]
35. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
France M; Rees A; Datta D; Thompson G; Capps N; Ferns G; Ramaswami U; Seed M; Neely D; Cramb R; Shoulders C; Barbir M; Pottle A; Eatough R; Martin S; Bayly G; Simpson B; Halcox J; Edwards R; Main L; Payne J; Soran H;
Atherosclerosis; 2016 Dec; 255():128-139. PubMed ID: 27839699
[TBL] [Abstract][Full Text] [Related]
36. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
Ito MK; Watts GF
Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
[TBL] [Abstract][Full Text] [Related]
37. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
[TBL] [Abstract][Full Text] [Related]
38. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
[TBL] [Abstract][Full Text] [Related]
39. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
40. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
